Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Accumulated Expenses: 2016-2019

Historic Other Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 4 years, with Dec 2019 value amounting to $9.5 million.

  • Akebia Therapeutics' Other Accumulated Expenses fell 39.38% to $10.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $10.3 million, marking a year-over-year decrease of 39.38%. This contributed to the annual value of $9.5 million for FY2019, which is 20.97% down from last year.
  • Akebia Therapeutics' Other Accumulated Expenses amounted to $9.5 million in FY2019, which was down 20.97% from $12.1 million recorded in FY2018.
  • In the past 5 years, Akebia Therapeutics' Other Accumulated Expenses registered a high of $12.1 million during FY2018, and its lowest value of $1.9 million during FY2016.
  • In the last 3 years, Akebia Therapeutics' Other Accumulated Expenses had a median value of $9.5 million in 2019 and averaged $8.0 million.
  • In the last 5 years, Akebia Therapeutics' Other Accumulated Expenses spiked by 410.00% in 2018 and then decreased by 20.97% in 2019.
  • Akebia Therapeutics' Other Accumulated Expenses (Yearly) stood at $1.9 million in 2016, then grew by 21.74% to $2.4 million in 2017, then skyrocketed by 410.00% to $12.1 million in 2018, then decreased by 20.97% to $9.5 million in 2019.